Retroclival ecchordosis physaliphora: MR imaging and review of the literature.

BACKGROUND AND PURPOSE: Ecchordosis physaliphora (EP), found in about 2% of autopsies, is a clinically inconspicuous notochordal remnant appearing at the dorsal wall of the clivus. To our knowledge, a systematic review of its MR features does not exist. The aim of this study was to describe the MR imaging findings of incidentally found retroclival EP with special respect to its differentiation from intradural chordomas. METHODS: We reviewed 300 consecutive 1.5-T MR imaging studies that included thin-section transverse T2-weighted images of the skull base for the presence of a retroclival EP. In cases in which an EP was identified, two neuroradiologists observed MR signal intensity characteristics, contrast enhancement, size, form, stalk of EP, and signal intensity changes of the adjacent clivus. RESULTS: Five cases with retroclival EP were found (incidence, 1.7%). In all cases, the ecchordoses was hyperintense on T2-weighted images and hypointense on T1-weighted images. Contrary to the reported findings in chordomas, none of the lesions showed contrast enhancement. In four cases, there were signal intensity changes in the adjacent clivus. A stalklike connection between clivus and EP was seen in three patients. CONCLUSION: Because of the benign character of EP and the difficulties in its histopathologic differentiation from chordomas, precise knowledge of the radiologic characteristics of EP is important. On the basis of these five cases and a review of literature, contrast enhancement and the presence of clinical symptoms seem to be highly reliable parameters in the differential diagnosis of intradural chordoma and EP.

Clinical evaluation of a computer simulated prediction model of contrast enhancement of the liver in spiral CT.

OBJECTIVE: A software program was developed simulating a compartmental model of blood circulation based on differential equations. The aim of this study was to compare software-simulated levels of hepatic enhancement with the true values in patients and to test how many patients reach the simulated hepatic enhancement level. METHODS: As software program the CT application software carebolus 2 (Siemens, Forchheim, Germany) was used. Hepatic contrast-enhancement curves were simulated prior to CT examinations to evaluate a patient specific time delay after contrast application. At the time delay, when the simulation curve showed an enhancement threshold of 40 Hounsfield Units (HU), the CT spiral scan was started applying 120 ml contrast media with 2 ml/s. The simulated curves were compared with the empiric curves of each patient. RESULTS: 25 of 28 patients (89%) achieved 40 HU. The mean enhancement of empiric patients curves was 46.32 +/- 11.9 HU, the mean simulated enhancement was 46.62 +/- 4.3 HU S.D. (P= 0.48). 4.4 values per patient liver could be compared with the simulation curve (122 points for 28 patients): 50% of the patient curves were within a range of 5 HU compared with the simulation curve. CONCLUSION: Software simulation of contrast enhancement curves of the liver is a feasible and valuable method to predict individual liver enhancement curves. Improvements concerning the integration of cardiovascular parameters and preexisting liver parenchymal diseases into the simulation software have to be arranged.